Back to top
more

Genocea Biosciences, Inc. (GNCA)

(Real Time Quote from BATS)

$2.12 USD

2.12
50,884

-0.05 (-2.30%)

Updated Feb 20, 2020 12:53 PM ET

Add to portfolio

2-Buy   2      

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1
2
3
4
5
S&P
Strong Buy
Buy
Hold
Sell
Strong Sell
500
24.47%
17.86%
9.49%
5.20%
2.00%
10.75%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

F Value | B Growth | C Momentum | C VGM

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

View All Zacks #1 Ranked Stocks

Trades from $1

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Zacks News

Zacks Equity Research

Genocea Biosciences Enters Oversold Territory

Genocea Biosciences has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

GNCA

Kinjel Shah

Buy These 7 Small Drugmakers to Boost Your Portfolio's Health

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaborations and M&A activity have kept small drugmakers afloat in a competitive market.

NBIX GNCA REPH ZTS CPRX FLXN VRCA

Zacks Equity Research

Are Options Traders Betting on a Big Move in Genocea Biosciences (GNCA) Stock?

Investors need to pay close attention to Genocea Biosciences (GNCA) stock based on the movements in the options market lately.

GNCA

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for March 20th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 20th

SIC RDY GNCA CLAR

Zacks Equity Research

Will Genocea Biosciences Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor in Genocea Biosciences.

GNCA

Zacks Equity Research

Top Ranked Momentum Stocks to Buy for March 7th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 7th

OPHT LZB KALV GNCA

Zacks Equity Research

Genocea Biosciences Sees Hammer Chart Pattern: Time to Buy?

Genocea Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.

GNCA

Zacks Equity Research

Genocea Biosciences (GNCA) Jumps: Stock Rises 24.8%

Genocea Biosciences (GNCA) was a big mover last session, as the company saw its shares rise almost 25% on the day amid huge volumes.

JAZZ GNCA

Zacks Equity Research

Are Options Traders Betting on a Big Move in Genocea Biosciences (GNCA) Stock?

Investors in Genocea Biosciences (GNCA) need to pay close attention to the stock based on moves in the options market lately.

GNCA

Zacks Equity Research

GENOCEA BIOSCIENCES (GNCA) Catches Eye: Stock Gains 7.1%

GENOCEA BIOSCIENCES, INC. (GNCA) moved big last session, as its shares rose over 7% on the day.

GRFS GNCA

Zacks Equity Research

Genocea Biosciences (GNCA) Jumps: Stock Moves 12% Higher

Genocea Biosciences, Inc. (GNCA) shares rose almost 12% in the last trading session.

GNCA NEOS

Zacks Equity Research

Should You Sell Genocea Biosciences (GNCA) Before Earnings?

Investors are always looking for stocks that are poised to beat at earnings season and Genocea Biosciences, Inc. (GNCA) may be one such company.

GNCA

Zacks Equity Research

Genocea Stock Up on Positive Genital Herpes Infections Data

Genocea Biosciences, Inc. (GNCA) announced encouraging six-month data from a planned interim analysis of its ongoing placebo-controlled phase IIb study on GEN-003 for the treatment of genital herpes infections.

ARNA ANIK CBM GNCA

Tracey Ryniec

How to Find Winning Biotech Stocks

The biotechs are a gamble but here are some guidelines to lessen the risk.

BBC MACK GNCA JUNO